Epigallocatechin Gallate Destabilizes α-Synuclein Fibril by Disrupting the E46-K80 Salt-Bridge and Inter-protofibril Interface
- PMID: 33186020
- DOI: 10.1021/acschemneuro.0c00598
Epigallocatechin Gallate Destabilizes α-Synuclein Fibril by Disrupting the E46-K80 Salt-Bridge and Inter-protofibril Interface
Abstract
The accumulation and deposition of fibrillar aggregates of α-synuclein (α-syn) into Lewy bodies are the major hallmarks of Parkinson's disease (PD) for which there is no cure yet. Disrupting preformed α-syn fibrils is considered one of the rational therapeutic strategies to combat PD. Experimental studies reported that epigallocatechin gallate (EGCG), a polyphenol extracted from green tea, can disrupt α-syn fibrils into benign amorphous aggregates. However, the molecular mechanism of action is poorly understood. Herein, we performed molecular dynamics simulations on a newly released Greek-key-like α-syn fibril with or without EGCG to investigate the influence of EGCG on α-syn fibril. Our simulations show that EGCG disrupts the local β-sheet structure, E46-K80 salt-bridge crucial for the stabilization of the Greek-key-like structure, and hydrophobic interactions stabilizing the inter-protofibril interface and destabilizes the global structure of the α-syn fibril. Interaction analyses reveal that hydrophobic and hydrogen-bonding interactions between EGCG and α-syn fibrils play important roles in the destabilization of the fibril. We find that the disruption of the E46-K80 salt-bridge closely correlates with the formation of hydrogen-bonds (H-bonds) between EGCG and E46/K80. Our results provide mechanistic insights into the disruption modes of α-syn fibril by EGCG, which may pave the way for designing drug candidates targeting α-syn fibrillization to treat PD.
Keywords: Parkinson’s disease; disruption mechanism; epigallocatechin gallate; molecular dynamics simulation; protein aggregation; α-synuclein.
Similar articles
-
EGCG attenuates α-synuclein protofibril-membrane interactions and disrupts the protofibril.Int J Biol Macromol. 2023 Mar 1;230:123194. doi: 10.1016/j.ijbiomac.2023.123194. Epub 2023 Jan 7. Int J Biol Macromol. 2023. PMID: 36623616
-
Unravelling the destabilization potential of ellagic acid on α-synuclein fibrils using molecular dynamics simulations.Phys Chem Chem Phys. 2023 Mar 15;25(11):8128-8143. doi: 10.1039/d2cp06006j. Phys Chem Chem Phys. 2023. PMID: 36877087
-
How oxidized EGCG remodels α-synuclein fibrils into non-toxic aggregates: insights from computational simulations.Phys Chem Chem Phys. 2023 Jul 19;25(28):19182-19194. doi: 10.1039/d3cp02261g. Phys Chem Chem Phys. 2023. PMID: 37431676
-
Green Tea Epigallocatechin-3-gallate (EGCG) Targeting Protein Misfolding in Drug Discovery for Neurodegenerative Diseases.Biomolecules. 2021 May 20;11(5):767. doi: 10.3390/biom11050767. Biomolecules. 2021. PMID: 34065606 Free PMC article. Review.
-
α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.Biochim Biophys Acta Proteins Proteom. 2019 Oct;1867(10):890-908. doi: 10.1016/j.bbapap.2019.03.001. Epub 2019 Mar 7. Biochim Biophys Acta Proteins Proteom. 2019. PMID: 30853581 Review.
Cited by
-
Targeting Protein Aggregates with Natural Products: An Optional Strategy for Neurodegenerative Diseases.Int J Mol Sci. 2023 Jul 10;24(14):11275. doi: 10.3390/ijms241411275. Int J Mol Sci. 2023. PMID: 37511037 Free PMC article. Review.
-
Effect of Electric Field on α-Synuclein Fibrils: Revealed by Molecular Dynamics Simulations.Int J Mol Sci. 2023 Mar 28;24(7):6312. doi: 10.3390/ijms24076312. Int J Mol Sci. 2023. PMID: 37047286 Free PMC article.
-
Amyloid Disassembly: What Can We Learn from Chaperones?Biomedicines. 2022 Dec 17;10(12):3276. doi: 10.3390/biomedicines10123276. Biomedicines. 2022. PMID: 36552032 Free PMC article. Review.
-
Epigallocatechin-3-gallate: A phytochemical as a promising drug candidate for the treatment of Parkinson's disease.Front Pharmacol. 2022 Sep 12;13:977521. doi: 10.3389/fphar.2022.977521. eCollection 2022. Front Pharmacol. 2022. PMID: 36172194 Free PMC article. Review.
-
Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson's disease.J Neurol. 2022 Nov;269(11):5762-5786. doi: 10.1007/s00415-022-11267-9. Epub 2022 Jul 13. J Neurol. 2022. PMID: 35831620 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
